Radioimmunotherapy is being considered for its potential role in treating indolent lymphoma. The therapy has been studied for its safety and efficacy in non-Hodgkin's lymphoma, with some research focusing on specific treatments such as 90Y-ibritumomab and 131I-Tositumomab. Its use is being explored as both a follow-up treatment and as an initial treatment option for certain types of lymphoma, including follicular lymphoma.